linjc16/ctgov huggingface dataset:
Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to investigate sexual function in patients suspected of non muscle invasive bladder cancer (NMIBC). The investigators hypothesis is that reduced sexual function is underdiagnosed in patients with non-muscle invasive bladder cancer and that active examination and treatment may worsen the sexual function.

Official Title
-----------------
Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer

Conditions
-----------------
Hematuria, Urinary Bladder Neoplasms, Sexual Dysfunction, Physiological, Sexual Dysfunctions, Psychological, Erectile Dysfunction

Intervention / Treatment
-----------------
* Other: EORTC QLQ-C30 and EORTC BLS-24 questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with primary hematuria, both gross and microscopic Men and women older or equal to 40 years of age Signed informed consent statement Exclusion Criteria: Men and women younger than 40 years of age Patients with recurrent hematuria and known causative disease Already known urogenital cancer Previous massive pelvic surgery or pelvic radiotherapy TUR-P within the last 2 months Participants diagnosed with tumors originating from the ureters, renal pelvis and kidney, and bladder tumors at T stage more than or equal to T1b.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hematuria - NMIBC<br>Primary hematuria due to NMIBC. | Other: EORTC QLQ-C30 and EORTC BLS-24 questionnaire<br>* Questionnaires answered at baseline and 4 months follow up.<br>|
| Hematuria - other cause<br>Other non-malignant cause of hematuria. | Other: EORTC QLQ-C30 and EORTC BLS-24 questionnaire<br>* Questionnaires answered at baseline and 4 months follow up.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in sexual function | Change in sexual function measured by the EORTC QLQ-BLS24 sexual functioning questions | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in erectile function | Change in erectile function measured by the Erection Hardness Scale | 4 months |
Database of All Patients With Microbiologically Proven Mycobacteria Tuberculosis Infection

Study Overview
=================
Brief Summary
-----------------
Prospective data collection of all patients with microbiologically proven mycobacteria tuberculosis infection treated at Singapore General Hospital.

Detailed Description
-----------------
Tuberculosis currently infects one third of the world's population and is responsible for killing approximately 2 million individuals annually. This is a major public health concern worldwide, and there has been a huge impetus to implement strategies for better tuberculosis control. The investigators have established a system to track all patients with microbiologically proven tuberculosis treated at Singapore General Hospital, with vigilant recording and reporting systems, from the first instance when patients were diagnosed to the time they have completed anti-tuberculosis chemotherapy. The investigators endeavour to use this system to improve patient care by adopting patient-supportive approaches that lead to high compliance rates and best possible outcomes of treatment.

Official Title
-----------------
Prospective Database of All Patients With Microbiologically Proven Mycobacteria Tuberculosis Infection Treated at Singapore General Hospital

Conditions
-----------------
Tuberculosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) All patients with microbiologically proven mycobacteria tuberculosis infection treated at the Singapore General Hospital.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Final outcomes of patients who have been diagnosed with microbiologically proven mycobacteria tuberculosis infection at Singapore General Hospital |  | From diagnosis to final outcome | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tuberculosis
Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)

Study Overview
=================
Brief Summary
-----------------
Background and study aim The relative risks of duodenal adenocarcinoma and ampullary carcinoma in Familial Adenomatous Polyposis (FAP) have been estimated 100 to 330 times higher than in general population. However risk factors, including a genotype-phenotype association for duodenal cancer in FAP has not been fully understood. The aim of this study is to determine risk factors associated with the development of advanced duodenal polyposis and ampullary adenomas in colectomized patients with FAP.

Official Title
-----------------
Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis: A Prospective Clinical, Immunopathologic and Molecular Analysis

Conditions
-----------------
Familial Adenomatous Polyposis

Intervention / Treatment
-----------------
* Procedure: Duodenoscopy and enteroscopy
* Genetic: Molecular analysis.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Familial Adenomatous Polyposis with colectomy, or scheduled for surgery. Exclusion Criteria: Pregnancy, lactation

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Duodenoscopy and enteroscopy|All patients will undergo duodenoscopy and classified according to Spigelman. Patients classified as Spigelman III and IV will undergo enteroscopy.|
|Genetic: Molecular analysis.|DNA analysis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genetic profile in FAP patients |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Familial Adenomatous Polyposis
Sperm Quality in Consecutive Sperm Samples After 4-7 Days and 2 Hours of Sexual Abstinence

Study Overview
=================
Brief Summary
-----------------
The main purpose of the study is to assess to which degree a series of sperm parameters known to be associated with fertilization and implantation potential in artificial reproductive technology (ART) differ in consecutive sperm samples produced after 2-7 days and 2 hours of sexual abstinence in males from couples referring for ART treatment.

Official Title
-----------------
Parameters of Sperm Quality in Consecutive Sperm Samples From Males Partners of Couples Seeking Treatment for Infertility

Conditions
-----------------
Semen Quality

Intervention / Treatment
-----------------
* Other: 2-7 days of Sexual abstinence
* Other: 2 hours of sexual abstinence


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male age between 18 and 50 able to understand and read Danish Exclusion Criteria: complete azospermia significant psychological illness significant cardiovascular disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Ejaculate 1<br>Semen sample after 2-7 days of sexual abstinence | Other: 2-7 days of Sexual abstinence<br>* 2-7 days of Sexual abstinence<br>|
| Active Comparator: Ejaculate 2<br>Semen sample after 2 hours of sexual abstinence | Other: 2 hours of sexual abstinence<br>* 2 hours of sexual abstinence<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Routine semen quality assessment | Routine sperm quality check including Morphology, Motility and DNA fragmentation index using both the conventional manual method and computer assisted sperm analysis (CASA) systems. | After liquefaction (30-35 minutes after ejaculation) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Outcome of ART treatments | assessing and correlating the sperm quality with the results of the ART procedures | up to one year after the sampling | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Semen quality, Sexual Abstinence, sperm motility, DNA fragmentation
Pattern of Growth and Characteristics of Down Syndrome Pediatrics Patients

Study Overview
=================
Brief Summary
-----------------
Down syndrome or Down's syndrome (DS), also known as trisomy 21, is a genetic disorder caused by the presence of all or part of a third copy of chromosome 21. It is usually associated with physical growth delays, mild to moderate intellectual disability, and characteristic facial features. The parents of the affected individual are usually genetically normal. The probability increases from less than 0.1% in 20-year-old mothers to 3% in those of age 45 .

Detailed Description
-----------------
People with DS may have some or all of these physical characteristics: a small chin, slanted eyes, poor muscle tone, a flat nasal bridge, a single crease of the palm, and a protruding tongue due to a small mouth and relatively large tongue. Other features include: a flat and wide face, a short neck, excessive joint flexibility, extra space between big toe and second toe, abnormal patterns on the fingertips and short fingers. Short stature is a characteristic feature of DS. Growth retardation of DS individuals starts prenatally. After birth, the growth velocity is most reduced between 6 months to 3 years . Growth charts specific for children with DS are important tools for routine medical follow-up, as well as early identification of pathological causes of growth retardation, and monitoring of growth promoting treatments. Growth charts for DS are available from different countries, for example, Italy, USA, Denmark, Sweden, Portugal, France, UK and Ireland and Saudi Arabia .

Official Title
-----------------
Pattern of Growth and Characteristics of Down Syndrome Pediatrics Patients Attending Assuit University Children Hospital

Conditions
-----------------
Growth Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All Down syndrome children attending Assuit university less than four years with or without cardiovascular. Exclusion Criteria: Any Down syndrome child more than four years.

Ages Eligible for Study
-----------------
Maximum Age: 4 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Down syndrome less than four years Group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The pattern of growth in Down syndrome patients | Descriptive case series study | 6 months |
En Face  OCT's Contribution in the Detection of Macular Retinal Toxicity Signs Linked to the Chronic Treatment of Synthetic Antimalarials

Study Overview
=================
Brief Summary
-----------------
The maculopathy induced by the retinal toxicity of the synthetic antimalarials must be detected at the infra-clinical state, when it can still be reversible. Identifying early retinal anatomical changes has always represented (a challenge for medical interns, dermatologists, rheumatologists, and ophthalmologists). Currently, the gold-standard for its screening and its diagnostic is the multifocal electroretinogram (mfERG), however it is a long and tedious exam, offered by only few medical centers. It is recommended to find a simple non-invasive alternative, on a commonly used equipment. The study of the ellipsoid (junction line between, the external and internal photoreceptor segments) using optical coherence tomography (OCT-SD) en face enables us, to obtain a panoramic viewing of the state of the photoreceptor layer, and to detect any modification, even subtle, within this layer. The OCT-SD en face can be easily done by any ophthalmologist who owns one. The proportion of en face OCT-SD showing suggestive retinal damage and patients who present retinal damage in relation with synthetic antimalarial treatments and diagnosed by mfERG is considered in this study.

Conditions
-----------------
Maculopathy

Intervention / Treatment
-----------------
* Device: spectral domain optical coherence tomography
* Device: multifocal electroretinogram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients treated with synthetic antimalarials with retinal damage (in relation with the antimalarial treatment) recently diagnosed by mfERG Patients treated with synthetic antimalarials in the past, who stopped treatment because of a supposed retinal damage not confirmed by mfERG Exclusion Criteria: - State of ocular structures preventing the realization of exams

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: En face OCT (C-scan)<br> | Device: spectral domain optical coherence tomography<br> <br> Device: multifocal electroretinogram<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| concordance between mfERG and En-face OCT | measure of kappa coefficient | after 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Toxicity, Drug
Rapid On-site Cytopathologic Evaluation in the Diagnosis of Hilar/Mediastinal Adenopathy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether rapid on-site cytopathologic evaluation (ROSE) can increase the diagnostic yield of transbronchial needle aspiration (TBNA) in the diagnosis of hilar and mediastinal lymphadenopathy.

Official Title
-----------------
Transbronchial Needle Aspiration With and Without Rapid On-site Cytopathologic Evaluation in the Diagnostic Approach to Hilar/Mediastinal Adenopathy: A Randomized Controlled Trial.

Conditions
-----------------
Lung Cancer, Sarcoidosis, Tuberculosis

Intervention / Treatment
-----------------
* Procedure: Rapid on-site cytopathologic evaluation (ROSE)
* Procedure: TBNA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years old and older Hilar and/or mediastinal lymphadenopathy (> 1 cm on the short axis, as assessed by contrast-enhanced CT scan (computed tomography)) Exclusion Criteria: Uncontrolled coagulopathy Refusal to sign informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: TBNA alone<br>Arm A: TBNA alone. | Procedure: TBNA<br>* transbronchial needle aspiration<br>|
| Experimental: TBNA with ROSE<br>Arm B: TBNA with ROSE. | Procedure: Rapid on-site cytopathologic evaluation (ROSE)<br>* ROSE: examination in the endoscopy suite, by a pathologist, during the bronchoscopic procedure, of samples obtained with transbronchial needle aspiration.<br>Procedure: TBNA<br>* transbronchial needle aspiration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Examine the diagnostic yield of the TBNA with ROSE arm versus the diagnostic yield of TBNA alone arm |  | 6-12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Examine the percentage of inadequate samples in the TBNA with ROSE arm versus the TBNA alone arm |  | 6-12 months | 
| Examine the number of biopsy sites in the TBNA with ROSE arm versus the TBNA alone arm |  | 6-12 months | 
| Examine the complication rate of bronchoscopy in the TBNA with ROSE arm versus the TBNA alone arm |  | 6-12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transbronchial needle aspiration, Bronchoscopy, Rapid on-site cytopathologic evaluation, Mediastinal lymphadenopathy, Hilar Lymphadenopathy
Bioactive Composite Versus Resin-Modified Glass Ionomer Liners: 2-Year Clinical Trial

Study Overview
=================
Brief Summary
-----------------
compare 2-year clinical performance of recent bioactive ionic resin composite to resin-modified glass ionomer liner in indirect dental pulp treatment.

Detailed Description
-----------------
patients were enrolled in the clinical trial. Each patient had two deep carious lesions, one on each side of the mouth. After selective caries removal, cavities were lined with bioactive ionic resin composite (Activa Bioactive Liner/Base) or resin-modified glass ionomer liner (Riva Light Cure RMGI). All cavities were then restored with nanofilled resin composite (Filtek Z350xt). All materials were placed according to the manufacturers' instructions. Clinical evaluation was accomplished using World Dental Federation (FDI) criteria at baseline and after 6 months, one year, one and half years, and two years.

Official Title
-----------------
Bioactive Ionic Resin Composite Versus Resin-Modified Glass Ionomer Cavity Liners: 2-Year Randomized Clinical Trial

Conditions
-----------------
Dental Caries

Intervention / Treatment
-----------------
* Other: ACTIVA bioactive
* Other: Riva LC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presence of two deep carious lesions, one on each side of the mouth (ICDAS 5 or 6) vital teeth no sensitivity to teeth percussion no spontaneous pain no radiolucency in the periapical or furcation area of teeth complete and normal occlusion good oral hygiene Exclusion Criteria: poor oral hygiene severe or chronic periodontal problems periapical lesions heavy bruxism non-vital teeth visibly cracked teeth spontaneous dental pain sensitivity to teeth percussion

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: ACTIVA bioactive<br>bioactive ionic resin composite | Other: ACTIVA bioactive<br>* bioactive ionic resin composite<br>|
| Other: Riva LC<br>Resin-modifed glass ionomer | Other: Riva LC<br>* resin-modified glass ionomer<br>* Other names: Riva light cure;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assess clinical performance of bioactive ionic resin composite and resin-modified glass ionomer liner by using FDI clinical criteria | comparison of 2-year clinical performance of recent bioactive ionic resin composite( ACTIVA bioactive) to resin-modified glass ionomer liner ( Riva LC) in indirect dental pulp treatment using FDI world dental federation clinical criteria. | 2-years |
Autologous Bone Marrow Cell Treatment in Peripheral Atherosclerosis

Study Overview
=================
Brief Summary
-----------------
Implantation of bone marrow cells, including endothelial progenitor cells, into ischemic limbs has been shown to improve collateral vessel formation. In the present study the safety and feasibility of autologous blood mononuclear cells implantation will be investigated in patients with severe peripheral atherosclerosis.Twenty cases will be enrolled. Improvement in the ankle-brachial pressure index (ABI:>0.1), ischemic ulcers and angiography as well as laser doppler flow will be evaluated until six months.

Official Title
-----------------
Autologous Bone Marrow Cell Treatment in Patients With Peripheral Atherosclerosis

Conditions
-----------------
Peripheral Vascular Diseases

Intervention / Treatment
-----------------
* Genetic: Autologous bone marrow cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of third or fourth class of peripheral atherosclerosis Exclusion Criteria: Insuline dependent diabetes Cancer

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: Autologous bone marrow cells|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical and instrumental indexes of functional impairment of peripheral atherosclerosis. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Angiographic and laser doppler measurements after six months from treatment. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Peripheral arterial disease,, blood marrow cells,, therapeutic angiogenesis.